AbbVie (ABBV)

These healthcare dividend stocks appeal to investors in different ways.

With stocks arguably priced like it's 1999, these three dividend payers could help you weather what comes next.

The world's largest healthcare company is making shrewd investments in its future.

AbbVie, Merck and Gilead Sciences offer growing dividends alongside pipeline-driven growth, making pharmaceutical stocks a defensive option as investors seek shelter from market volatility.

Value stocks are crushing growth stocks as investors sour on the artificial intelligence trade.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

These are arguably among the most reliable dividend payers.

They have both outperformed the broader equity market over the long run.

AbbVie posted Q3 revenue of $17.4 billion and raised EPS guidance as Skyrizi and Rinvoq offset Humira's decline, prompting analyst price target hikes and a stock move to fresh highs.

AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.

AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.

AbbVie replaced one megablockbuster already. It may have found its next one.

AbbVie’s third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Managem...

Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety.

Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with sales up 10.3% year on year to $17.4 billion. Its non-GAAP ...

Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance.

AbbVie (NYSE:ABBV) reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and neuroscience portfolios. The company posted adjusted earnings per share of $3.82, $0.07 above the midpoi

Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non...

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what to expect. AbbVie beat analysts’ revenue expect...

Despite its high price relative to earnings, AbbVie remains an attractive stock.

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.